PMID- 36452227
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221202
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of oncolytic virus combined with chemotherapy or immune 
      checkpoint inhibitors in solid tumor patients: A meta-analysis.
PG  - 1023533
LID - 10.3389/fphar.2022.1023533 [doi]
LID - 1023533
AB  - Background: In recent years, several clinical trials have focused on oncolytic 
      virus (OVs) combined with chemotherapy or immune checkpoint inhibitors (ICIs) in 
      solid tumor patients, which showed encouraging effects. However, few studies have 
      concentrated on the summary on the safety and efficacy of the combined 
      treatments. Therefore, we conducted this meta-analysis to explore the safety and 
      curative effect of the combined therapy. Methods: We searched the PubMed, 
      Cochrane Library, Embase, and Clinicaltrials.gov databases to comprehensively 
      select articles on OVs combined with chemotherapy or ICIs for the solid tumor 
      treatment. Overall survival (OS), progression-free survival (PFS), 1-year 
      survival rate, 2-year survival rate, objective response rate (ORR), and adverse 
      events (AEs) were the outcomes. Results: Fifteen studies with 903 patients were 
      included in this meta-analysis. The pooled ORR was 32% [95% confidence interval 
      (CI): 27-36%, I(2) = 24.9%, p = 0.239]. Median OS and median PFS were 6.79 months 
      (CI: 4.29-9.30, I(2) = 62.9%, p = 0.044) and 3.40 months (CI: 2.59-4.22, I(2) = 
      0.0%, p = 0.715), respectively. The 1-year survival rate was 38% (CI: 0.29-0.47, 
      I(2) = 62.9%, p = 0.044), and the 2-year survival rate was 24% (CI: 12-37%, I(2) 
      = 0.0%, p = 0.805). The most common AEs were fever (63%, CI: 57-69%, I(2) = 2.3%, 
      p = 0.402), fatigue (58%, CI: 51-65%, I(2) = 49.2%, p = 0.096), chill (52%, CI: 
      43-60%, I(2) = 0.0%, p = 0.958), and neutropenia (53%, CI: 47-60%, I(2) = 0.0%, p 
      = 0.944). Conclusion: OVs combined with ICIs showed a better efficacy than OVs 
      combined with chemotherapy, which lends support to further clinical trials of OVs 
      combined with ICIs. In addition, OVs combined with pembrolizumab can exert 
      increased safety and efficacy. The toxicity of grades >/=3 should be carefully 
      monitored and observed. However, high-quality, large-scale clinical trials should 
      be completed to further confirm the efficacy and safety of OVs combined with 
      ICIs. Systematic Review Registration: 
      [https://www.crd.york.ac.uk/PROSPERO/login.php], identifier [RD42022348568].
CI  - Copyright (c) 2022 Liu, Zhang, Feng, Wang, Chen, Niu, Lu and Fang.
FAU - Liu, Xiangxing
AU  - Liu X
AD  - Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
FAU - Zhang, Jiaojiao
AU  - Zhang J
AD  - Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
FAU - Feng, Keqing
AU  - Feng K
AD  - Department of Clinical Pharmacy, Ocean University of China, Qingdao, China.
FAU - Wang, Simin
AU  - Wang S
AD  - Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
FAU - Chen, Liming
AU  - Chen L
AD  - Nursing Department, Peking University People's Hospital, Beijing, China.
FAU - Niu, Suping
AU  - Niu S
AD  - Clinical Trial Institution, Scientific Research Department, Peking University 
      People's Hospital, Beijing, China.
FAU - Lu, Qian
AU  - Lu Q
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, China.
FAU - Fang, Yi
AU  - Fang Y
AD  - Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
LA  - eng
PT  - Systematic Review
DEP - 20221114
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9702820
OTO - NOTNLM
OT  - ICIs
OT  - oncolytic virotherapy
OT  - oncolytic virus
OT  - oncolytic virus combination therapy
OT  - single-arm meta-analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/02 06:00
MHDA- 2022/12/02 06:01
PMCR- 2022/11/14
CRDT- 2022/12/01 02:40
PHST- 2022/08/19 00:00 [received]
PHST- 2022/10/24 00:00 [accepted]
PHST- 2022/12/01 02:40 [entrez]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/02 06:01 [medline]
PHST- 2022/11/14 00:00 [pmc-release]
AID - 1023533 [pii]
AID - 10.3389/fphar.2022.1023533 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Nov 14;13:1023533. doi: 10.3389/fphar.2022.1023533. 
      eCollection 2022.